Associated Genetic Biomarkers
ERBB2 G776V is present in 0.02% of AACR GENIE cases.
ERBB2 G776V is a predictive biomarker for use of ado-trastuzumab emtansine in patients.
Of the therapies with ERBB2 G776V as a predictive biomarker, 1 has NCCN guidelines in at least one clinical setting.
Non-small cell lung carcinoma has the most therapies targeted against ERBB2 G776V or its related pathways .
Ado-Trastuzumab Emtansine +
Non-Small Cell Lung Carcinoma -
|Biomarker Criteria:||Predicted Response: Primary Sensitivity|
|Clinical Setting(s): Metastatic (NCCN)|
|Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN.|
ERBB2 G776V serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 G776V as an inclusion criterion, 1 is phase 2 (1 open).
Trials with ERBB2 G776V in the inclusion eligibility criteria most commonly target breast carcinoma .
Neratinib is the most frequent therapy in trials with ERBB2 G776V as an inclusion criteria .
Significance of ERBB2 G776V in Diseases
Non-Small Cell Lung Carcinoma +
Breast Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.